

48 - References

References

48 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Robinson DG, et al. Psychopharmacological treatment in the RAISE-ETP study: outcomes of a manual and computer decision support system based intervention. *Am J Psychiatry* 2018; 175:169-179.
2. Zhu Y, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. *Lancet Psychiatry* 2017; 4:694-705.
3. Zhang JP, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. *Int J Neuropsychopharmacol* 2013; 16:1205-1218.
4. Leucht S, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. *Biol Psychiatry* 2005; 57:1543-1549.
5. Agid O, et al. The 'delayed onset' of antipsychotic action: an idea whose time has come and gone. *J Psychiatry Neurosci* 2006; 31:93-100.
6. Kahn RS, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. *Lancet Psychiatry* 2018; 5:797-807.
7. Subotnik KL, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. *JAMA Psychiatry* 2015; 72:822-829.
8. Schreiner A, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. *Schizophr Res* 2015; 169:393-399.
9. Alphs L, et al. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. *Early Interv Psychiatry* 2018; 12:55-65.
10. Kane JM, et al. Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable anti psychotics): results from the recruitment phase of the PRELAPSE trial. *J Clin Psychiatry* 2019; 80:18m12546.
11. Agid O, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. *J Clin Psychiatry* 2011; 72:1439-1444.
12. Drosos P, et al. One-year outcome and adherence to pharmacological guidelines in first-episode schizophrenia: results from a consecutive cohort study. *J Clin Psychopharmacol* 2020; 40:534-540.

13. Rajalingham K. Clozapine delay results in poorer outcomes for treatment-resistant schizophrenia patients. *Psiquiatría Biológica* 2024; 31:100493.
 14. Davis JM, et al. A meta-analysis of the efficacy of second-generation antipsychotics. *Arch Gen Psychiatry* 2003; 60:553-564.
 15. Leucht S, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009; 373:31-41.
 16. Schooler N, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry* 2005; 162:947-953.
 17. Oosthuizen PP, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. *J Clin Psychiatry* 2003; 64:1075-1080.
 18. Whiskey E, et al. Evaluation of an antipsychotic information sheet for patients. *Int J Psychiatry Clin Pract* 2005; 9:264-270.
 19. Stroup TS, et al. Results of phase 3 of the CATIE schizophrenia trial. *Schizophr Res* 2009; 107:1-12.
 20. Olofinjana B, et al. Antipsychotic drugs: information and choice: a patient survey. *Psychiatr Bull* 2005; 29:369-371.
 21. Stroup TS, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 2006; 163:611-622.
 22. Haro JM, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. *J Clin Psychopharmacol* 2006; 26:571-578.
 23. Novick D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. *Schizophr Res* 2009; 108:223-230.
 24. Tiihonen J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ* 2006; 333:224.
 25. Leucht S, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry* 2009; 166:152-163.
 26. Remington G, et al. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. *Schizophr Res* 2007; 90:229-237.
 27. McCutcheon R, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. *Acta Psychiatr Scand* 2018; 137:39-46.
 28. Takeuchi H, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. *Neuropsychopharmacology* 2019; 44:1036-1042.
 29. McEvoy JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 2006; 163:600-610.
 30. Lewis SW, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. *Schizophr Bull* 2006; 32:715-723.
 31. Mace S, et al. Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics. *Ther Adv Psychopharmacol* 2019; 9:2045125319860977.
-

Revision #1

Created 2026-01-04 20:13:46 UTC by Omar Ayman

Updated 2026-01-04 20:13:46 UTC by Omar Ayman